Disitamab vedotin combined with pyrotinib as salvage treatment in Her-2-amplified treatment refractory metastatic colorectal cancer: a case report
BackgroundHuman epidermal growth factor receptor 2 (HER-2) amplification has been identified in approximately 3% of patients with metastatic colorectal cancer (mCRC). Owing to the lack of established anti-ERBB2 therapeutic approaches, mCRC patients with Her-2 amplification rarely receive targeted tr...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1431422/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|